

Genetron Holdings Limited

1Q 2021 Financial Results

May 2021

The following presentation has been prepared by Genetron Holdings Limited (“Genetron Health” or the “Company”) solely for informational purposes and should not be construed to be, directly or indirectly, in whole or in part, an offer to buy or sell and/or an invitation and/or a recommendation and/or a solicitation of an offer to buy or sell any security or instrument or to participate in any investment or trading strategy, nor shall any part of it form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities or otherwise. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. Nothing contained in this document shall be relied upon as a promise or representation as to the past or future performance of the Company. Past performance does not guarantee or predict future performance. You acknowledge that any assessment of the Company that may be made by you will be independent of this document and that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

This document contains certain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1953, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, with respect to the Company’s future financial or business performance, strategies or expectations. These statements typically contain words such as “believe,” “may,” “will,” “could,” “expects” and “anticipates” and words of similar import. Any statement in this document that is not a statement of historical fact is a forward-looking statement and involves known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by such forward-looking statements. There can be no assurance that the results and events contemplated by the forward looking statements contained herein will in fact occur. None of the future projections, expectations, estimates or prospects in this document should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of assumptions, fully stated in the document. The Company also cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time and which may be beyond the Company’s control. The Company assumes no duty to and does not undertake to update any forward-looking statements to reflect actual results, changes in assumptions or changes in factors affecting these statements. Factors that may materially affect our results and those risks listed in filings with the Securities and Exchange Commission.

This document also contains non-IFRS financial measures, the presentation of which is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with International Financial Reporting Standards. In addition, the Company’s calculation of these non-IFRS financial measures may be different from the calculation used by other companies, and therefore comparability may be limited. The reconciliation of those measures to the most comparable IFRS measures is contained within this document or available at our website <http://ir.genetronhealth.com>.

This document speaks as of May 24, 2021. Neither the delivery of this document nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since that date.

China's leading precision oncology company

Three Proprietary Technology Platforms



One-step Seq



Mutation Capsules



FusionScan

Total Addressable Market

Market potential in China⁽¹⁾

#1 in China for Biopharma Partners

~40 Total Biopharma Partners

Biopharma Services
TAM \$0.5bn

Diagnosis & Monitoring
TAM \$6.7bn

Early Screening
\$7.2bn liver
TAM \$5.8bn lung
\$23bn CRC

#1 in China for IVD approved products

Top 3 in China for LDT Revenue

7 Products in Pipeline
2-day TAT for S5+Lung 8

1st Published Liver Cancer Prospective Study

Source: Frost & Sullivan
(1) Market potential as of 2023

- Recent Events Recap
- Early Screening –HCCscreen™ Updates
- Early Screening – Mutation Capsule
- IVD Business Update
- 1Q2021 Financials
- Milestones and Growth Strategy
- Appendix

Financial

- Total revenue **RMB 92.1 million** for 1Q2021, **19.8% y/y revenue growth**. Excluding Covid test revenue of RMB 16.6 million in 1Q2020, total revenue grew **52.9% y/y**
- **Gross margin improved to 59.3%** vs 55.0% in 1Q2020

Operational/ Strategic

- Exclusive partnership for **HCCscreen™** with Sino Biopharm's subsidiary, **Chia Tai Tianqing**
 正大天晴药业集团
CHIA TAI TIANQING PHARMACEUTICAL GROUP
- Strategic partnership with **Siemens Healthineers**  to promote large-scale application of **Genetron's S5 platform and lung cancer 8-gene IVD assay**
- Strategic cooperation with **JD Health**  京东健康, a subsidiary of JD.com, Inc., to jointly create an **internet innovation model for full-cycle cancer solutions**

Research

- New prospective **HCCscreen™** data - **88% sensitivity, 93% specificity, 40.9% PPV, 99.3% NPV**

(1) Chinese Anti-Cancer Association Guidelines for Patients with Primary Liver Cancer


- Recent Events Recap
- Early Screening –HCCscreen™ Updates
- Early Screening – Mutation Capsule
- IVD Business Update
- 1Q2021 Financials
- Milestones and Growth Strategy
- Appendix

HCCscreen™ Investigational Study (the “HIT” Study)


- Collaboration study started in 2019 with the **National Cancer Center**
- **Multi-center study**
- **2,000 HBsAg+ patients** were tested by HCCScreen™ and Ultrasound + AFP
- Completed follow-up work for **1,615 cases**

| HCCscreen™ Test | Clinical Diagnosis | | |
|-----------------|--------------------|---------|-------|
| | HCC | Non-HCC | Total |
| Test - Positive | 76 | 110 | 186 |
| Test - Negative | 10 | 1,419 | 1,429 |
| Total | 86 | 1,529 | 1,615 |

Sensitivity
(76/86)



Specificity
(1419/1529)



40.9%



Positive Predictive Value (PPV)
(76/186)

99.3%


Negative Predictive Value (NPV)
(1419/1429)


- HCCscreen™ demonstrated **excellent sensitivity in detecting early-stage HCC**
- These patients are expected to have much better prognosis than advanced-stage

| HCCscreen™ Test | Tumor Size | | | Total |
|--------------------|------------|-----------|----------|-----------|
| | <3cm | 3-5cm | >5cm | |
| Test positive | 28 | 22 | 7 | 57 |
| Test negative | 5 | 1 | 1 | 7 |
| Total | 33 | 23 | 8 | 64 |



Early Screening – Updates on HCCscreen™



- Powered by Genetron's innovative and proprietary **Mutation Capsule** Technology
- Received **U.S. FDA** breakthrough designation – expands geographical reach 

JDH 京东健康

Aim to jointly create an internet innovation model for full-cycle cancer solutions

iKang 爱康
iKang Medical Exam



NCC
NATIONAL CANCER CENTER
国家癌症中心



江苏无锡(惠山)生命科技产业园
Jiangsu Wuxi (Huishan) Life Science & Technology Industrial Park
L-PARK


Selected by the NCC/Wuxi government for public health initiative

正大天晴药业集团
CHIA TAI TIANGING PHARMACEUTICAL GROUP

Partnership with CTTQ (30%+ share in hepatitis antiviral drugs, 7000+ sales reps, and 2000+ hospitals)





- Recent Events Recap
- Early Screening –HCCscreen™ Updates
- Early Screening – Mutation Capsule
- IVD Business Update
- 1Q2021 Financials
- Milestones and Growth Strategy
- Appendix

Mutation Capsule – Our Innovative and Proprietary Technology



Source: Pantel et al., *Nat Rev Clin Oncol*, 2019

Features and Advantages:

-  In parallel profiling of **mutation and methylation markers**
-  **De novo discovery of methylation sites**
-  Support **multiple tests** from a single ctDNA sample
-  **Strong performance** with significant time and cost savings

- Recent Events Recap
- Early Screening –HCCscreen™ Updates
- Early Screening – Mutation Capsule
- IVD Business Update
- 1Q2021 Financials
- Milestones and Growth Strategy
- Appendix

Winning the China market – entering into hospitals

Starting from LDT then evolving into “LDT + IVD”

Laboratory developed test (LDT)


- Initially hospitals unable to run complex NGS testing in house
- Third party labs provide service to hospitals
- Fast adoption of latest technology



In vitro diagnostics (IVD)

- Generate incremental revenue for hospitals
- Currently the only pathway to public medical insurance
- Lengthy large size clinical trials required by NMPA

We provide LDTs to ~500 top hospitals in China, and we are actively selling IVDs to them




Targeting ~1000 Class 3 Grade A hospitals for cancer treatment in China

~290
Internal direct sales and marketing representatives

Teamed up with **SIEMENS Healthineers** to advance the use of **Genetron S5 platform and lung cancer 8-gene IVD assay** in hospitals

LDT **500+** hospitals ordered tests from us

IVD **42** in-hospital partners ⁽¹⁾ including **23** IVD In-hospital partners ⁽²⁾



(1) The number of total in-hospital partners include both sales of LDT services and IVD products.
(2) By March 31, 2021


- Recent Events Recap
- Early Screening –HCCscreen™ Updates
- Early Screening – Mutation Capsule
- IVS Business Update
- **1Q2021 Financials**
- Milestones and Growth Strategy
- Appendix

1Q2021 revenue growth drivers:

- LDT: Driven by rapid early screening adoption, as well as growth in LDT diagnostic tests
- IVD: Year-over-year decrease was due to Covid-19 testing revenue of RMB 16.6M which was booked in 1Q20. Without this, IVD sales grew 490.3%
- Development services: Continued strategic shift to biopharma services


Robust revenue growth in 1Q2021

of LDT tests



Note:
(1) Unaudited financial numbers
(2) Excluded Covid-19 testing revenue in 1Q2020


LDT revenue as a percentage of total revenue increased in 1Q2021



First Quarter 2021 Gross Margin


Gross profit and margin

(RMB million)




Gross profit and margin (LDT)

(RMB million)




Gross profit and margin (IVD)

(RMB million)



Gross profit and margin (Development services)

(RMB million)




Note:
(1) Unaudited financial numbers

First Quarter Operating expenses


Selling expenses

(RMB million)




Administrative expenses

(RMB million)



R&D expenses

(RMB million)



■ Selling expenses ■ Percentage of total revenue

■ Administrative expenses ■ Percentage of total revenue

■ R&D expense ■ Percentage of total revenue

Note:
(1) Unaudited financial numbers


First Quarter 2021 unaudited financial highlights

| (in RMB million) | First Quarter | | |
|----------------------------------|---------------|---------|------------|
| | Q1 2021 | Q1 2020 | Y/Y Change |
| Revenue | 92.1 | 76.8 | 19.8% |
| Diagnosis & monitoring- LDT | 71.8 | 47.6 | 51.0% |
| Diagnosis & monitoring- IVD | 15.3 | 19.2 | (20.5)% |
| Development services | 5.0 | 10.1 | (50.6)% |
| Gross margin | 59.3% | 55.0% | 430bps |
| Selling expenses (% of rev) | 64.8% | 70.0% | (520)bps |
| R&D expenses (% of rev) | 54.3% | 36.0% | 1830bps |
| Admin expenses (% of rev) | 48.4% | 28.1% | 2030bps |
| Operating loss | (109.0) | (67.2) | 62.3% |
| Net loss | (115.0) | (115.5) | (0.4)% |
| Non-IFRS loss ¹ | (105.8) | (65.6) | 61.2% |
| Ending cash balance ² | 1,069.0 | 180.9 | 491.0% |

1. Non-IFRS loss represents net results excluding share-based expenses, fair value change and other loss of financial instruments with preferred rights. Please refer to appendix for the reconciliation of non-IFRS loss for the year/period to net loss for the year/period

2. Cash and Cash Equivalents

(RMB million)




- Recent Events Recap
- Early Screening –HCCscreen™ Updates
- Early Screening – Mutation Capsule
- IVD Business Update
- 1Q2021 Financials
- **Milestones and Growth Strategy**
- Appendix




Upcoming pipeline catalysts


Screening:





Diagnosis & Monitoring / CDx:



Well-positioned to become a prominent liquid biopsy player



Develop liquid biopsy-based solutions across the full-cycle cancer management
Continue to ramp up our commercialization efforts




- Recent Events Recap
- Early Screening –HCCscreen™ Updates
- Early Screening – Mutation Capsule
- IVD Business Update
- 1Q2021 Financials
- Milestones and Growth Strategy
- Appendix

Reconciliation of non-IFRS net loss to net loss for the period

UNAUDITED NON-IFRS FINANCIAL MEASURES

| | For the three months ended, | |
|--|-----------------------------|------------------|
| | March 31, 2020 | March 31, 2021 |
| | RMB'000 | RMB'000 |
| Loss for the period | (115,460) | (115,038) |
| Adjustments: | | |
| Share-based compensation | 5,051 | 9,250 |
| Fair value loss of financial instruments with preferred rights | 44,779 | |
| Non-IFRS Loss | (65,630) | (105,788) |
| Attributable to: | | |
| Owners of the Company | (65,630) | (103,504) |
| Non-controlling interests | | (2,284) |



ANSWERS FOR CANCER